Arvinas reports Phase 1 Parkinson’s trial data showing ARV-102-linked gains in oculomotor measure

PUBT · 2d ago
Arvinas reports Phase 1 Parkinson’s trial data showing ARV-102-linked gains in oculomotor measure
  • Arvinas presented final Phase 1 data on ARV-102 in Parkinson’s disease at the 2026 MDS meeting in Seoul.
  • Results supported central nervous system exposure, LRRK2 degradation, improved objective eye-movement function, with biomarker shifts consistent with disease-relevant pathway modulation.
  • Exploratory analyses linked biomarker reductions with eye-movement changes, supporting continued clinical evaluation despite no efficacy design.
  • The 28-day study tested oral dosing versus placebo in 24 patients, informing next-step development for LRRK2-related neurodegenerative diseases.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arvinas Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610070700PRIMZONEFULLFEED9841091) on October 07, 2026, and is solely responsible for the information contained therein.